Abstract:The peptidoglycan-polysaccharide (PGPS) model shares many etiologic and pathologic features with Crohn's disease (CD).Anti-TNFα therapy reduces both inflammation and fibrosis in the PGPS model if begun early but, as in CD, has diminished efficacy when instituted late in the course of the model.To begin to tease out the mechanism of diminished anti-TNFα efficacy in advanced disease, we examined changes in mRNA levels of a broad panel of proinflammatory and profibrotic factors over time in the PGPS model.Methods: PGPS or human serum albumin (HSA, control) was injected into the bowel wall of Lewis rats at laparotomy.Rats (1 HSA, 3 PGPS) were euthanized at each time point (1, 4, 7, 11, 14, 21, and 28 d post injection).Non-operated rats (3) served as d0 controls.In separate experiments, rats received Ab501 (CA156_00501 Fab'-PEG; a pegylated murinized rabbit anti-mouse TNF) beginning on d1 or d13.Rats receiving anti-TNF were studied on d12 or d28.Gross abdominal score (sum of adhesions, mesenteric thickening, cecal wall thickening, cecal nodules, and liver nodules on 0-4 scales) was determined.A pathologist scored cecal sections.Quantitative real-time PCR was performed on cecal tissue.Results: IL1 β, IL6, TNFα, and TGFβ1 mRNAs showed a biphasic response, peaking at d1 and again at d11 post PGPS injection (previously shown).The second peak at d11 was accompanied by maximal mRNA levels of Th1 (IFNγ, IL2) and Th17 (IL17A) cytokines, IL23, granulocyte-macrophage colony stimulating factor (GM-CSF), monocyte chemotactic protein-1, arginase-1, tissue transglutaminase 2, and tissue inhibitor of metalloproteinase 1. Osteopontin mRNA was maximally elevated at d1 (.500-fold), then progressively declined to ~40-fold control at d21-28.IL13 mRNA was not elevated.Anti-TNF begun on d1 decreased expression of IL1 β (5.5±1.8 v 12.8±1.2,p=0.014) and IL6 (11.2±6.6 v 51.5±7.6,p=0.008) when assessed on day 12. Anti-TNF begun on d13 did not change expression of TNF α, IL1β, IL6 mRNAs; procollagens I and III trended higher on d21 (col I: 23.1±6.2v 11.6±1.9,p=0.07; col III: 14.7±2.1 v 9.14±1.7,p=0.06).Conclusions: The robust Th17 response and increased GM-CSF near the midpoint of the PGPS model time course may render the ongoing immune response no longer controllable by targeting TNF α alone.Blockade of TNF α activity initiated at times in the course of disease when TGF β1 mRNA expression is maximal could exaggerate the results of loss of TNF α inhibitory effects on TGF β profibrotic activity.This could explain why anti-TNFα begun on d13 results in increased collagen mRNA at d21.Decreased tissue compliance, suggested by increased collagen deposition at d7, may play a role in triggering the d7-11 wave of increased profibrotic and proinflammatory factors.Cytokine milleu and tissue factors likely determine the effect of anti-TNF on tissue inflammation and fibrosis.

Blockage of Tumor Necrosis Factor Prevents Intestinal Mucosal Inflammation Through Down-Regulation of Interleukin-23 Secretion

Relationship between anti-tumor necrosis factor -α monoclonal antibody and chronic colitis in mice.

Anti-TNF- α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease.

Effect of Anti-Tnf-α Antibody on Mucosal Lymphocyte Apoptosis in Chronic Colitis Mice

Tumor Necrosis Factor Suppresses Interleukin 10 in Peripheral B Cells Via Upregulating Bcl2-like Protein 12 in Patients with Inflammatory Bowel Disease.

Blockade of CD28/CTLA-4-B7 Costimulatory Pathway in Colitic SCID Mice

Blocking Tnf-Alpha By Combination Of Tnf-Alpha- And Tnfr-Binding Cyclic Peptide Ameliorates The Severity Of Tnbs-Induced Colitis In Rats

Anti-tumour Necrosis Factor Therapy Enhances Mucosal Healing Through Down-Regulation of Interleukin-21 Expression and T Helper Type 17 Cell Infiltration in Crohn's Disease

Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease

Tumour Necrosis Factor Alpha (tnfα) Vaccines in the Downregulation of Bowel Inflammatory Responses in Mice

Recombinant Tumor Necrosis Factor Alpha (TNF alpha) Peptide-Based Vaccine Ameliorates Acute and Chronic Murine Colitis

Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions1

Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response

Sa1797 Cell Cycle Arrest, DNA Damage and Remodeling of the Colonic Epithelial Barrier Composition and Function Underlies DSS-Induced Colitis

Inhibition of the Interleukin-23/Interleukin-17 Pathway by Anti-Interleukin-23p19 Monoclonal Antibody Attenuates 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Crohn'S Disease in Rats

Blocking TNF-α by Combination of TNF-α- and TNFR-binding Cyclic Peptide Ameliorates the Severity of TNBS-induced Colitis in Rats.

TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice

TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability

The Increased Expression of IL-23 in Inflammatory Bowel Disease Promotes Intraepithelial and Lamina Propria Lymphocyte Inflammatory Responses and Cytotoxicity.

Increased Expression of Interleukin-23 Induces Proinflammatory Cytokine Secretion in Inflammatory Bowel Disease

Blockade of Complement Activation Product C5a Activity Using Specific Antibody Attenuates Intestinal Damage in Trinitrobenzene Sulfonic Acid Induced Model of Colitis